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B LYMPHOCYTE RANKL ENHANCES PERIODONTAL DISEASE IN  
 
TYPE 2 DIABETES 
 
JOSEPH JAE-SUNG LEE 
ABSTRACT 
 
 Periodontitis (PD) and type 2 diabetes (T2D) are inflammatory diseases, 
which have B lymphocyte dysfunction in subjects with both conditions. B 
lymphocytes, when activated, release receptor activator of nuclear factor kappa-
B ligand (RANKL), which is a key element for osteoclastogenesis and periodontal 
related bone loss. Previous studies have looked at PD or T2D but not together 
within the context of inflammation. To further understand the impact of T2D 
potentiated periodontal complications, purified B lymphocytes from mice spleen 
were plated on dentin plates under both stimulated and unstimulated conditions 
alone and as co-cultures with T lymphocytes to determine the effect on dentin pit 
formation, a measure of bone loss. Pit area analysis showed that stimulated B 
lymphocytes from obese mice had significantly higher pit areas when compared 
to all lean conditions (B/T unstimulated and stimulated).  Because obese B 
lymphocytes had the largest pit areas, this correlated with the highest 
osteoclastic activity. This supports the hypothesis that T2D contributes to 
periodontal disease bone loss specifically through B lymphocyte RANKL function. 
These results suggest that B lymphocytes may be a therapeutic drug target that 
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can provide new clinical treatments to control T2D potentiated periodontal 
complications. 
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INTRODUCTION 
Periodontitis and type 2 diabetes 
Type 2 Diabetes mellitus (T2D) affects populations everywhere with the 
current number of adults with T2D estimated to be 425 million and projected to 
increase by more than 50% in the next twenty years [1]. T2D is a metabolic 
disorder that is characterized by hyperglycemia, hyperinsulinemia, insulin 
resistance and chronic inflammation. Like T2D, periodontitis (PD) is a common 
chronic inflammatory disease that affects about 750 million people worldwide. PD 
has been closely linked to T2D in clinical studies [2, 3], and epidemiological 
studies have shown that periodontal disease risk within the diabetic population is 
increased by threefold compared to non-diabetic individuals [3]. Because of the 
high prevalence of T2D and the subpopulation with PD, it is important to address 
the risks and comorbidities of these chronic diseases. To further elucidate the 
dynamic relationship between T2D and PD, many studies have focused on the 
effect of one disease on the other, yielding evidence that chronic inflammation 
from PD can negatively affect glycemic control and T2D can increase risk for PD 
[4, 5]. The combination of PD and diabetes can fuel a feed-forward loop leading 
to increased inflammatory signaling and elevated levels of cytokines such as 
TNF-, IL-6, and IL-8 [4]. Because inflammation is positively correlated amongst 
obesity, T2D, and PD, it is imperative to understand its connection to the 
progression of these diseases.  
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Inflammation in periodontal disease 
Periodontal disease starts with gingivitis, which is defined by inflammation 
limited in the gingiva, and is reversible with proper oral hygiene. If left untreated, 
gingivitis can lead to PD, in which the inflammation is extended to the soft tissue 
and can cause alveolar bone resorption, resulting in bone loss of the maxilla 
and/or mandible. The inflammatory response from PD includes an immune 
response via activation of B and T lymphocytes, with progressive periodontal 
lesions characterized by increased prominence of B lymphocytes [7]. B 
lymphocytes have several functions as part of the adaptive immune system 
which include secreting antibodies, production of cytokines, and antigen 
presentation [8, 9]. There is a positive correlation between PD and increased IgG 
antibody, a generally inflammatory B cell product, in response to oral pathogens 
in the gingival cavity [10]. Notably, B lymphocytes had similar cytokine production 
including pro-inflammatory and pro-osteoclastogenic cytokine TNF- in both PD 
and T2D subjects, suggesting B lymphocytes play a central role in linking T2D-
associated complications that worsen periodontitis [4, 11, 12].  In PD studies 
independent of T2D, Chen et al (2014) recovered B and T lymphocytes from 
diseased human periodontal tissues, and showed that more than 90% of B 
lymphocytes express RANKL whereas 54% of T lymphocytes express RANKL. 
Additionally, B lymphocytes were not dependent on T lymphocytes to drive bone 
resorption [13]. In another study, Han et al (2006) injected congenitally athymic 
donor mice with B lymphocytes specific for Actinomycetemcomitans into non-
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immune mice and found that increased B cell response lead to increased RANKL 
expression in actinomycetemcomitans-immunized animals which lead to higher 
levels of osteoclast differentiation leading to increased periodontal bone 
resorption in absence of T lymphocytes [7].  
Oral inflammation, mainly from immune cells, has important downstream 
implications for oral bone health as cytokines such as TNF-and IL-1b which 
increase differentiation and activity of osteoclasts. Osteoclasts are cells that 
resorb bone [14]. The TNF-family Receptor Activator of Nuclear Factor κB 
(RANK) initiates differentiation of osteoclasts and is essential for developing 
mature osteoclasts [15, 16]. However, there is controversy on the cellular source 
of RANK-ligand (RANKL). Suda et al, 1999 showed that osteoblasts are the main 
source of the RANKL that is required for murine osteoclast differentiation under 
co-culture conditions [17]. However, other studies question this interpretation by 
showing osteocytes expressed RANKL for regulation of osteoclastogenesis, and 
that RANKL produced by osteoblasts or their progenitors did not contribute to 
bone remodeling [18-21]. Furthermore, many studies found B and T lymphocytes 
to be the major sources of RANKL [7, 10, 22, 23]. Our lab showed B lymphocytes 
play a major role in PD and osteoclastogenesis in obese T2D hosts, in part due 
to support of the PD-associated cytokines TNF-, IL-8, and IL-1B, although 
RANKL trends failed to reach statistical difference. In contrast, this work found 
that T lymphocytes appear to be more significant for PD in lean subjects although 
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T cell RANKL was not specifically measured [12]. Definitive tests on the 
importance of B or T cell RANKL in PD remain forthcoming. 
RANK, the receptor for RANKL, is one of the main pathways that trigger 
activation of Nuclear factor kappa-light-chain-enhancer of activated B 
lymphocytes (NF-κB) in osteoclasts [25, 26]. NF-κB is a transcription factor 
complex that has various functions best understood in immune and inflammatory 
responses, but also plays roles in osteoclastogenesis [24]. The RANK/RANKL 
pathway signals by binding to TNF receptor associated factors (TRAF6), which 
triggers the downstream target NF-κB [29, 30]. Osteoprotegerin (OPG) also 
regulates RANK signaling-mediated activation, thus the NF-κB required for 
osteoclastogenesis [27, 28]. OPG acts as a decoy receptor for RANKL and 
RANKL-OPG binding inhibits the RANK pathway (Figure 1). 
Taken together, previous studies suggest that altered B cell functions, 
including increased proinflammatory cytokines and antibody production may 
bridge the gap between T2D and PD in vivo [12, 33]. The purpose my work was 
to specifically test the hypothesis that T2D-linked changes in B cell RANKL 
activity specifically promotes osteoclastogenesis towards supporting T2D-
associated periodontal disease. 
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Figure 1. RANKL pathway. RANKL - Receptor activator for NF-κB Ligand, OPG 
– Osteoprotegerin, RANKL - Receptor activator for NF-κB, TRAF6 - TNF receptor 
associated factor 6, NF-κB - Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
  
  
 6 
 
METHODS AND MATERIALS 
Mice 
Five-week old male mice (DIO-B6-M; C57BL/6N) were fed ad libitum with 
a high fat diet (HFD) (N=11, 60% calories from fat; Research Diets D12492i- 
irradiated) or a comparable low fat diet (LFD) (N=11, 10% calories from fat; 
Harlan Teklad irradiated) for 10 weeks, except a 6-hr food deprivation period 
before blood draws for fasting glucose levels. Metabolic measurements were 
performed on 9 weeks and 15 weeks of diet for glucose tolerance by Intra-
peritoneal glucose tolerance test (IPGTT). Blood glucose levels were measured 
by glucometer by scoring the tip of the tail and measuring at 0, 10, 20, 30, 60, 90, 
and 120 minutes. The body weight of mice was measured weekly and just prior 
to sacrifice at 16 weeks diet (21 weeks of age).  
 
Preparation of Splenocytes 
Mice were euthanized by CO2 narcosis and were placed on a clean 
dissection board and the animal’s skin was sterilized with 70% alcohol. The 
abdominal cavity was exposed by making an incision on the left side of the 
abdomen and the spleen was removed and placed into a conical tube containing 
RPMI medium 1640 (Gibco Life Technologies).  
Splenocyte suspension was prepared by placing the spleen onto a 70-
micron cell strainer that was submerged in RPMI medium in a 3-cm petri dish; 
spleen was minced through the strainer using the plunger end of a syringe. The 
 7 
 
cells were washed through the strainer with RPMI, then transferred to a 15ml 
conical tube and centrifuged at 1,200 rpm for 10 minutes. The supernatant was 
aspirated and the cell pellet was resuspended in 3 mL of red blood cell (RBC) 
lysis buffer (eBiosciences) at 37ºC in the same conical tube. The cells were 
incubated with RBC lysis buffer at room temperature for 6 minutes and then 12 
mL of RPMI was added. Cells were centrifuged again at 1,200 rpm for 10 
minutes. The supernatant was discarded and the cell pellet was resuspended in 
phosphate buffered saline (PBS) (Corning Incorporated) with 1% Bovine Serum 
Albumin (BSA – Fraction V) for cell sorting (Figure 2).  
 
Fluorescence-activated cell sorting (FACS) Cell Sorting 
The splenocyte cell suspension was stained with an antibody cocktail 
containing live/dead indicator (Zombie aqua), the hematopoietic cell marker 
CD45, the B cell-specific markers CD19 and CD20, and the T cell specific marker 
CD4. The cells were then washed and resuspended in 3 ml of the FACS buffer 
(PBS with 1% BSA). A total of 400,000 B and T lymphocytes were sorted into 10 
ml of RPMI medium. B and T cell suspensions were centrifuged at 1,200 rpm for 
10 minutes and the final cell pellets were resuspended in RPMI medium at a 
concentration of 50,000 cells per 50 l (106 cells/ml) prior to testing in 
osteoclastogenesis assays as outlined below.  
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RAW cell preparation 
Adherent mouse LMM (RAW 264.7, Mouse leukemic monocyte-
macrophage) cells were removed from plates by aspirating cell line media and 
adding 500 l of PBS based non-enzymatic cell detaching buffer. This cell 
suspension was incubated for 5 minutes at 37℃ and the cells were detached by 
cell pipetting. Suspended cells were transferred to 15ml conical tube with 4.5ml 
of Dulbecco's Modified Eagle Medium High glucose (4.5g/L) (DMEM) with 10% 
FBS, 1% penicillin/streptomycin and L-glutamine (4.0 mM). Cells were 
centrifuged at 1200 RPM for 10 minutes and the supernatant aspirated before 
the cells were resuspended in Minimum Essential Medium Eagle - Alpha 
Modification (modified MEM) with 10% FBS, 1x penicillin/streptomycin and l-
glutamine. The cells were counted on a hemocytometer and the cell suspension 
was diluted to a density of 1 x 104 cells/ml using modified MEM. Diluted cell 
suspension was transferred to a 96 well flat bottom plate to give a final count of 
1000 cells per well. After 6 hours of incubation, recombinant RANKL was added 
for pre-stimulation to the RAW cells.  
 
B and T cell Stimulation 
Unstimulated B and T lymphocytes (1000 cells each) were added to each 
well of 1000 RANKL-primed RAW cells. For B and T co-cultures, cells were 
added at a 10:1 ratio. For example, if the co-cultures were labeled “lean B cells 
with lean T cells”, we added 1000 B cells plus 100 T cells to 1000 RANKL-primed 
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RAW cells. RAW cells alone served as control for background and RAW cells + 
RANKL were the positive control. Alternatively, B lymphocytes were stimulated 
with 10 g/ml of E. coli lipopolysaccharides (LPS) (Invivogen), or T lymphocytes 
were stimulated withCD3/28 antibody coated Dynabeads (Life technology) for 
24hrs prior to addition to RAW cultures as detailed below. Supernatants from all 
lymphocyte cultures were collected for RANKL enzyme-linked immunosorbent 
assay after 24 hrs incubation. To prevent carry-over of lymphocyte stimuli to 
RANKL-primed RAW cells, B lymphocytes, T lymphocytes, and B cell/T cell co-
cultures were washed with RPMI 3 times prior to transfer. A second independent 
set of assays were performed on 96 well format dentin plates for pit formation. 
 
Pit formation on Dentin plates 
96 well flat bottom plates were used primarily for cell culture for both 
single and co-culture (Figure 2) of B and T lymphocytes. Cells incubated in 
standard 96 well plates (stimulated or unstimulated, Figure 2) were then moved 
to a second assay performed on 96 well dentin plates (Corning, 3988), which 
have a surface coating that mimic in vivo bone. The plate was incubated for at 
least 6 hrs to ensure cells adhered. The seeded cell were treated with RANKL for 
two days (pre-stimulation), then the media was changed to remove recombinant 
RANKL before addition of B and T lymphocytes for three days as below. These 
plates were used to quantify osteoclastic (bone resorption) activity via pit 
formation. 
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Tartrate-resistant acid phosphatase (TRAP) staining for osteoclast 
formation 
After 1000 RAW cells were plated on a 96 flat bottom plate, 100 µl of 
mouse RANKL (100 ng/ml) was prepared in modified MEM. 100 µl of this RANKL 
solution was added to each well to give a final concentration of RANKL of 50 
ng/ml. Then different combinations of B and T cells were added to each well 
(table 1). Media was changed every 2 days by removing 100 µl of culture 
medium and then adding 100 µl of fresh media containing the same 
concentration of mouse RANKL. After 5 to 7 days of incubation, the cells were 
stained using a Tartrate-resistant acid phosphatase (TRAP) stain to quantify 
number of osteoclasts per mm2. Osteoclasts are characterized by their TRAP 
expression.   
 
Pit Assay Analysis 
Dentin-coated wells were analyzed for clearance of dentin by each cell 
type. Dentin wells were treated with 1:4 bleach and von Kossa stain to show pit 
surface as dark under bright field. Digital images were taken with a Nikon camera 
and clearance positive zones in the well were counted and tabulated. All dentin 
plate images were uniform in size and pit areas were counted as pixels by 
coloring using Adobe Photoshop CC 2016 to calculate the number of pixels in the 
red-shaded region in-silico. A standard millimeter ruler was placed under 
microscope and images were taken at same conditions to calculate number of 
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 pixels/mm2 (1290614.147 pixels/mm2) and this was used to convert pit 
areas from digital images to total area in mm2.  
Statistical analysis of the data was performed by Graphpad Prism (version 
7) using 1-way ANOVA with Tukey post-hoc test for corrections for multiple 
comparisons. A p-value of < 0.05 was considered statistically different.  
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Figure 2. Summary of experimental design for TRAP stain and Pit assay. 
White boxes show TRAP protocol, gray boxes show PIT assay protocol, and 
Black boxes show addition of B and T cells in both experiments. 
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RESULTS 
Metabolic measurements of Mice 
 The HFD mice showed significantly higher body weight and fasting blood 
glucose compared to LFD mice. Intra-peritoneal glucose tolerance test (IPGTT) 
showed slower blood glucose clearance from HFD mice compared to LFD mice 
indicating a diabetic phenotype in the HFD mice (Figure 3).  
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Figure 3. Body weight and fasting blood glucose levels of mice on LFD and 
HFD at 15 weeks of diet. IPGTT on LFD and HFD mice at 15 weeks of diet 
Bars show average with points for each individual mouse. N=11 *p<0.05. 
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Sorting of Splenocytes 
There are four distinct groups in this experiment to assess in vitro 
osteoclastogenesis: lean B lymphocytes, obese B lymphocytes, lean T 
lymphocytes and obese T lymphocytes. The splenocytes from these mice were 
sorted for lymphocytes (Figure 4A) with debris shown on the bottom left and the 
dead cells being the scattered dots on the top right. Double discrimination based 
on side scatter and forward scatter (Figure 4B and 4C), which will exclude cells 
that are stuck together, leaving single cells only. Dead cells were excluded by 
zombie NIR live-dead stain (Figure 4D), macrophages were excluded using 
Cd11b+ surface marker (Figure 4E), and finally B lymphocytes (CD19+) and T 
lymphocytes (CD4+) are identified on the bottom left (Figure 4F). Cells were 
plated in single culture and co-culture combinations on dentin plates (Table 1).  
Table 1. All culture combinations for B and T cells 
 
TRAP Single Culture TRAP Co-Cultures 
RAW  (control) RR + Stim B Lean + Stim T Lean 
RAW + RANKL (RR) RR + Stim B Lean + Unstim T Lean 
RAW + RANKL + Anti-RANKL RR + Unstim B Lean + Stim T Lean 
RR + Unstim B Lean RR + Stim B obese + Stim T obese 
RR + Unstim B Obese RR + Stim B obese + Unstim T obese 
RR + Unstim T Lean RR + Unstim B obese + Stim T obese 
RR + Unstim T Obese RR + Stim B Lean + Stim T obese 
RR + Stim B Obese RR + Stim B obese + Stim T Lean 
RR + Stim B Obese + Anti-RANKL  
RR + Stim B Lean   
RR + Stim B Lean + Anti-RANKL  
RR + Stim T Obese  
RR + Stim T Obese + Anti-RANKL  
RR + Stim T Lean  
RR + Stim T Lean + Anti-RANKL  
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Figure 4. Flow cytometry gating. (A) Lymphocytes, (B) (C) single cells, (D) live 
cells, (E) CD45+ leukocytes, (F) CD4+ T helper cells and CD19+ B cells 
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 Tartrate-resistant acid phosphatase (TRAP) staining of osteoclasts in 
different culture combinations (Table 1) was used to visually quantify the number 
of osteoclasts per mm2 (Figure 5). RAW cells were used as control and 
background for trap staining (Figure 5a). RAW + RANKL is used as positive 
control with osteoclasts indicated by the black arrow (Figure 5b), RAW + RANKL 
+ anti-RANKL is used for negative control (Figure 5c), and TRAP seeding 
conditions (Figure 5d) which show osteoclastic activity in lean stimulated B cells 
as indicated by black arrow.     
    
 
 
 
 
 
 
 
 
 
 
Figure 5. Magnified images of TRAP stained cells in 96-well plates. (A) 
Control, (B) RAW cells with RANKL, (C) RAW + RANKL + anti-RANKL to show 
no osteoclasts, (D) RAW + RANKL + stimulated B cells from lean mice with an 
osteoclast indicated by black arrow.  
 
A B 
C D 
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TRAP staining analysis visually showed osteoclastic activity but proved to 
be difficult to quantify due to high background noise due to some non-specificity 
in staining. Analysis of trap data showed no significant differences in stimulated 
and unstimulated B and T cells (Figure 6).Therefore, pit assay on dentin plates 
was performed because of the increased sensitivity in staining with von Kossa 
and allowing more accurate analysis.  
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Figure 6. Quantified trap data showed no significant differences. White bars 
show lean and gray bars show obese. Significance was calculated by one-way ANOVA. 
Data are presented as mean ± SEM; *P < 0.05. 
 
Dentin plate analysis was blinded and an example of this is shown (Figure 
7A). Pits shown as lighter areas in the bright field were colored by h 
and to a specific type of red color identified by Photoshop (#ff0000) and 
the number of shaded pixels were calculated. Dentin plate of single culture 
showed no significant differences between lean B and lean T lymphocytes but 
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still induced some osteoclastogenesis in both stimulated and unstimulated 
conditions when compared to RAW (far left white bar) albeit non-significant 
(Figure 7B). In both obese B and T cells, stimulated cells were significantly 
higher than unstimulated cells which was expected. Stimulated obese B cells 
were significantly higher than lean stimulated B cells which recapitulates T2D 
associated changes in B cells enhances PD through RANKL as shown by dentin 
clearance. There was no significant differences between any of the unstimulated 
conditions between lean and obese.  
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Figure 7. Pit areas from stimulated obese B and T lymphocytes are 
significantly different form their unstimulated counterparts. (A) Magnified 
image of a dentin plate with pits (clearance of dentin). Pits were colored red manually 
and area was calculated by the number of pixels in the shaded area. (1290614.147 
pixels per 1 mm2), (B) Positive control for osteoclastogenesis: RAW (Mouse leukemic 
monocyte-macrophage), +/-RANKL as labeled. RAW cells -RANKL show background. 
Pit areas indicate osteoclast differentiation and function in the presence of stimulated 
and unstimulated B and T lymphocytes from lean and obese mice as indicated. 
Lymphocytes from lean mice similarly induced osteoclastogenesis, regardless of 
stimulation conditions (left, gray bars). Significant differences in cultures containing cells 
from obese mice were calculated by two-way ANOVA. Data are presented as mean ± 
SEM; *P < 0.05.  
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In order to determine if RANKL is required for osteoclastogensis, the 
RANKL pathway was inhibited to see if there would be any expected loss in pit 
formation. Anti-RANKL antibody inhibits the interaction between RANK and 
RANKL which suppresses osteoclastic activity which is observed by significant 
reduction in pit area (Figure 8). Isotype antibody are antibodies that are non-
specific to RANKL but match the type and class of the primary antibody (anti-
RANKL). This acts as a negative control to differentiate nonspecific antibody 
signal from the specific antibody signal. As shown in Figure 8, there was no 
significant differences between RAW+RANKL and RAW+RANKL+ISO-Ab.  
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Figure 8. Inhibition of RANKL by anti-RANKL antibody significantly  
reduced pit area.  RAW cells alone (black bars) show pit formation under conditions 
indicated at the bottom. White bars (on right) show pit formation by RANKL-primed RAW 
264.7 cells in the presence of B lymphocytes from obese mice with additional treatments 
as indicated at bottom. Significant differences in pit formation are calculated by one-way 
ANOVA. Data are presented as mean ± SEM; ***P < 0.001. 
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Figure 9. Single and co-cultures of stimulated and unstimulated B and T 
lymphocytes. Co-culture ratios are 1000:100 cells shown as written. Significantly 
different groups are calculated by one-way ANOVA. Data are presented as mean ± 
SEM; *P < 0.05. 
 
Stimulated and unstimulated B and T were co-cultured to determine their relative 
osteoclastic activity through RANKL production and the pit areas were calculated 
(Figure 9). Because B lymphocytes were shown previously to have the most 
RANKL driven osteoclastogenesis, they were cultured along with T lymphocytes 
to determine if there was any difference in B cell activity. Interestingly, lean 
stimulated B lymphocytes when co-cultured with lean stimulated T lymphocytes 
had significantly larger pit areas than the co-culture of obese stimulated B and T 
lymphocytes. This is contrary to single culture where lean stimulated B 
lymphocytes had smaller pit areas relative to obese stimulated B lymphocytes 
(Figure 7b). There was no significant difference amongst the unstimulated co-
cultures. This may suggest that T lymphocytes have some effect on osteoclastic 
activity when co-cultured with B lymphocytes within lean hosts.  
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DISCUSSION 
 
 Both T2D and periodontitis are common, and it is well established that 
T2D predisposes periodontitis, while the ability of periodontitis to worsen 
complications of T2D such as glycemic control remaining controversial [3]. It is 
vital to be able to identify sources of periodontal inflammation or drivers of 
periodontal bone loss to develop new methods of treatment to reduce 
periodontitis in patients with T2D. Our data has shown that B lymphocytes from 
T2D mice significantly increase pit area therefore increase osteoclastogenesis 
when compared to B lymphocytes from lean mice as determined in the pit area 
assay. Trends toward increased osteoclastogenesis in T lymphocytes remained 
statistically insignificant despite replication (N=11). Furthermore, there was no 
significant difference comparing pit area in the presence of B or T lymphocytes 
from lean hosts. This data agrees with previous findings which state that T 
lymphocytes alone do not drive PD in T2D [4]  
 T2D and PD have also been associated with delayed spontaneous 
apoptosis of peripheral blood neutrophils (PMN) and Manosudprasit et al (2016) 
showed that individuals with T2D and PD had relatively longer delays in 
apoptosis compared to T2D alone [34]. Because delayed neutrophil apoptosis 
advances organ dysfunction and potential organ failure, it is important to 
understand that individuals with both T2D and PD are vulnerable to various 
problems not limited to bone loss shown here [35]. Macrophage dysfunction has 
been shown to occur in mice fed a high fat diet in conjunction with oral 
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inoculation and also suggests that immune dysregulation may increase 
susceptibility of other bacterial infections [39].   
 Future directions for this study can look into the multiplicity of infection of 
P. gingivalis in both B and T cells to measure the cytokine profile of different 
intesities of P. gingivalis infection. While this current study supports the 
hypothesis of B cell driven osteoclastogenesis in T2D/PD subjects on dentin 
plates, it is unclear whether there is a minimum threshold of infection which may 
cause a domino effect resulting in periodontitis. Furthermore, combinations of 
bacteria are almost universal in PD so the next step would be looking into other 
PD related bacteria such as T. forsythia and to understand if there is any 
synergism between different bacteria in driving this disease. The next important 
step would be to look at a human model of periodontitis as classical pro-
inflammatory cytokines in T2D such as TNF-, IL-1β and IL-6 promote PD [36]. It 
would also be critical to look into human periodontal tissue to quantitate RANKL 
expression in B cells and T cells as potential targets for local immunotherapy. 
This strategy, applied systemically, could prove to be a promising avenue for 
other bone disorders such as rheumatoid arthritis, osteoporosis, or multiple 
myeloma [11, 37, 38]. 
 Dentin plate analysis described in this project provides accurate evidence 
which show obese B lymphocytes can be more osteoclastogenic and pit 
formation in obese mice is increased compared to their lean counterparts. The 
data indicates T2D increases B cell function to further advance periodontal bone 
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loss in a mouse model. Further cytokine profiling can be done through 
transcriptome arrays of B cells from both lean and T2D. This can look more 
closely at the mRNA of the cell after treatment of different cytokines to 
understand the cellular changes from abnormal cytokine levels. This dysfunction 
in B cells caused by excess cytokine production from T2D complications indicate 
B cells may be locally targeted through means like slow-release anti-CD20 
antibody such as Rituximab. This can target B cells with CD20 surface markers 
that could be useful in diseases such as PD/T2D, characterized by overactive B 
cells. Sequestration of the other B cell survival factors may be another method of 
locally targeting B cells for therapeutic purposes. This can translate our work 
towards a new clinical treatments be a potential drug target to control 
periodontitis.  
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